AnaptysBio (ANAB) news
Recent news
AnaptysBio Inc: H.C. Wainwright assumes coverage with buy rating; price target $95
AInvest Wire · Jun 10, 2026First Tracks Biopharmaceuticals Inc. <TRAX.O>: Wells Fargo initiates coverage with overweight rating and target price $30
Wells Fargo Securities has initiated coverage of First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), assigning an "Overweight" rating and a target price of $30 per share. The firm highlighted the company’s focused immunology portfolio and its progress in advancing key drug candidates, including…
AInvest Wire · Jun 8, 2026AnaptysBio rises 6% after results from rheumatoid arthritis treatment Rosnilimab
AnaptysBio rises 6% after results from rheumatoid arthritis treatment Rosnilimab AnaptysBio, Inc. (Nasdaq: ANAB) reported encouraging results from its Phase 2b trial for rosnilimab, a depleter and agonist targeting PD-1+ T cells, in patients with moderate-to-severe rheumatoid arthritis (RA). The…
AInvest Wire · Jun 3, 2025ImportantAnaptysBio resumes, gains 12% after Imsidolimab meets endpoint.
AInvest Wire · Oct 9, 2023ImportantAnaptysBio's skin disease drug meets main goal in late-stage study
AnaptysBio Inc said on Monday its experimental drug to treat a type of rare skin disease met the main goal in a late-stage study.
AInvest Wire · Oct 9, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.